Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

SyVento says bringing the FlexFactory to Poland makes new therapies available to patients in an efficient and high-quality way.

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

BioNTech plans to further investigate the drug’s potential in combination with mRNA vaccines, targeted therapies and ...

These targets include PNPLA3 where we are using an mRNA correction approach for those at high risk for a variety of liver ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies. For more information, ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...